| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $97.2M | +75.4% |
| SG&A Expense | $27.9M | +45.2% |
| Operating Income | -$125.1M | -67.6% |
| Interest Expense | $748K | — |
| Net Income | -$115.9M | -71.2% |
| EPS (Basic) | -$2.34 | -41.8% |
| EPS (Diluted) | -$2.34 | -41.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $164.0M | -15.2% |
| Short-term Investments | $0 | -100.0% |
| Current Assets | $166.7M | -31.8% |
| Total Assets | $185.0M | -27.0% |
| Current Liabilities | $27.1M | +69.4% |
| Total Liabilities | $32.7M | +87.4% |
| Stockholders' Equity | $152.3M | -35.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$88.2M | -64.8% |
| Capital Expenditures | $2.2M | +221.8% |
| Investing Cash Flow | $47.3M | +310.6% |
| Financing Cash Flow | $11.7M | -93.8% |
| Free Cash Flow | -$90.4M | -66.7% |